Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
J Immunol ; 162(10): 5728-37, 1999 May 15.
Article in English | MEDLINE | ID: mdl-10229805

ABSTRACT

Tumor cells gene-modified to produce GM-CSF potently stimulate antitumor immune responses, in part, by causing the growth and differentiation of dendritic cells (DC). However, GM-CSF-modified tumor cells must be gamma-irradiated or they will grow progressively, killing the host. We observed that 23 of 75 (31%) human tumor lines and two commonly used mouse tumor lines spontaneously produced GM-CSF. In mice, chronic GM-CSF production by tumors suppressed Ag-specific CD8+ T cell responses. Interestingly, an inhibitory population of adherent CD11b(Mac-1)/Gr-1 double-positive cells caused the observed impairment of CD8+ T cell function upon direct cell-to-cell contact. The inhibitory cells were positive for some markers associated with Ag presenting cells, like F4/80, but were negative for markers associated with fully mature DC like DEC205, B7. 2, and MHC class II. We have previously reported that a similar or identical population of inhibitory "immature" APC was elicited after immunization with powerful recombinant immunogens. We show here that these inhibitory cells can be elicited by the administration of recombinant GM-CSF alone, and, furthermore, that they can be differentiated ex vivo into "mature" APC by the addition of IL-4 and GM-CSF. Thus, tumors may be able to escape from immune detection by producing "unopposed" GM-CSF, thereby disrupting the balance of cytokines needed for the maturation of fully functional DC. Further, CD11b/Gr-1 double-positive cells may function as "inhibitory" APC under the influence of GM-CSF alone.


Subject(s)
Antigen-Presenting Cells/immunology , CD8-Positive T-Lymphocytes/immunology , Granulocyte-Macrophage Colony-Stimulating Factor/biosynthesis , Neoplasms, Experimental/immunology , Animals , Antigen-Presenting Cells/cytology , Antigen-Presenting Cells/drug effects , Antigens, Ly , Cell Communication , Cell Differentiation , Drug Interactions , Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology , Histocompatibility Antigens Class II/isolation & purification , Humans , Interleukin-4/pharmacology , Lymphocyte Culture Test, Mixed , Macrophage-1 Antigen , Mice , Spleen/cytology , Spleen/immunology , Tumor Cells, Cultured/immunology
2.
J Immunol ; 162(6): 3273-9, 1999 Mar 15.
Article in English | MEDLINE | ID: mdl-10092779

ABSTRACT

CD8+ T lymphocytes that specifically recognize tumor cells can be isolated and expanded ex vivo. While the lytic properties of these cells have been well described, their fate upon encounter with cognate tumor is not known. We performed reverse 51Cr release assays in which the lymphocyte effectors rather than the tumor cell targets were radioactively labeled. We found that melanoma tumor cells caused the apoptotic death of tumor-specific T cells only upon specific MHC class I-restricted recognition. This death was entirely blockable by the addition of an Ab directed against the Fas death receptor (APO-1, CD95). Contrary to the prevailing view that tumor cells cause the death of anti-tumor T cells by expressing Fas ligand (FasL), our data suggested that FasL was instead expressed by T lymphocytes upon activation. While the tumor cells did not express FasL by any measure (including RT-PCR), functional FasL (as well as FasL mRNA) was consistently found on activated anti-tumor T cells. We could successfully block the activation-induced cell death with z-VAD-fmk, a tripeptide inhibitor of IL-1 beta-converting enzyme homologues, or with anti-Fas mAbs. Most importantly, these interventions did not inhibit T cell recognition as measured by IFN-gamma release, nor did they adversely affect the specific lysis of tumor cell targets. These results imply that Fas-mediated activation-induced cell death could be a limiting factor in the in vivo efficacy of adoptive transfer of class I-restricted CD8+ T cells and provide a means of potentially enhancing their growth in vitro as well as their function in vivo.


Subject(s)
Apoptosis/immunology , Caspase Inhibitors , Lymphocyte Activation/immunology , Lymphocytes, Tumor-Infiltrating/immunology , Lymphocytes, Tumor-Infiltrating/pathology , Melanoma/immunology , fas Receptor/physiology , CD8-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/metabolism , CD8-Positive T-Lymphocytes/pathology , Cysteine Proteinase Inhibitors/pharmacology , Cytotoxicity Tests, Immunologic , Cytotoxicity, Immunologic , Epitopes, T-Lymphocyte/biosynthesis , Fas Ligand Protein , Humans , Lymphocytes, Tumor-Infiltrating/enzymology , Melanoma/enzymology , Melanoma/metabolism , Membrane Glycoproteins/physiology , Receptors, Antigen, T-Cell/metabolism , Tumor Cells, Cultured , fas Receptor/biosynthesis
3.
Cancer Res ; 59(1): 59-62, 1999 Jan 01.
Article in English | MEDLINE | ID: mdl-9892185

ABSTRACT

A recent report described the expression of Fas ligand (FasL) by melanoma cells as an important mechanism involved in the immune evasion by tumors [M. Hahne et al., Science (Washington DC), 274: 1363-1366, 1996]. To investigate the expression of FasL by melanomas, we screened a panel of early-passage cell lines by functional assay and reverse transcriptase-PCR. Using conditions designed to replicate those in the original report, we did not find functional FasL on any of the 19 human melanoma lines established at the National Cancer Institute. Furthermore, we additionally evaluated our melanoma lines using reverse transcriptase-PCR and found that 0 of the 26 human melanoma cell lines expressed FasL mRNA. FasL mRNA was abundantly expressed by anti-melanoma T-cell lines after activation. These data do not support a role for FasL expression in the escape of melanoma cells from immune destruction.


Subject(s)
Melanoma/immunology , Membrane Glycoproteins/biosynthesis , Fas Ligand Protein , Gene Expression Regulation, Neoplastic , Humans , Melanoma/pathology , Membrane Glycoproteins/genetics , Membrane Glycoproteins/immunology , RNA, Messenger/biosynthesis , RNA, Messenger/genetics , Tumor Cells, Cultured
4.
Cancer Immunol Immunother ; 47(2): 65-71, 1998 Oct.
Article in English | MEDLINE | ID: mdl-9769114

ABSTRACT

Fas (Apo-1/CD95) is a cell-surface protein that is responsible for initiating a cascade of proteases (caspases) culminating in apoptotic cell death in a variety of cell types. The function of the Fas/FasL system in the dampening of immune responses to infectious agents through the autocrine deletion of activated T cells has been well documented. More recently, it has been proposed that tumor cells express FasL, presumably to avoid immune detection. In this review, we focus on the role of the interaction of Fas and FasL in the modulation of antitumor responses. We critically examine the evidence that FasL is expressed by tumor cells and explore alternative explanations for the observed phenomena in vitro and in vivo. By reviewing data that we have generated in our laboratory as well as reports from the literature, we will argue that the Fas/FasL system is a generalized mechanism used in an autocrine fashion to regulate cell survival and expansion in response to environmental and cellular cues. We propose that FasL expression by tumor cells, when present, is indicative of a perturbed balance in the control of proliferation while "immune privilege" is established by "suicide" of activated antitumor T cells, a form of activation-induced cell death.


Subject(s)
Cell Communication/physiology , Neoplasms/immunology , Neoplasms/pathology , T-Lymphocytes/cytology , T-Lymphocytes/immunology , Animals , Apoptosis , Fas Ligand Protein , Humans , Immunotherapy , Lymphocyte Activation , Membrane Glycoproteins/biosynthesis , Membrane Glycoproteins/immunology , Neoplasms/therapy , fas Receptor/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...